A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Open accessThe DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.
Abstract
Major advances in understanding the pathogenesis of inherited metabolic disease caused by mitochondrial DNA mutations have yet to translate into treatments of proven efficacy. Leber's hereditary optic neuropathy is the most common mitochondrial DNA disorder causing irreversible blindness in young adult life. Anecdotal reports support the use of idebenone in Leber's hereditary optic neuropathy, but this has not been evaluated in a randomized controlled trial. We conducted a 24-week multi-centre double-blind, randomized, placebo-controlled trial in 85 patients with Leber's hereditary optic neuropathy due to m.3460G>A, m.11778G>A, and m.14484T>C or mitochondrial DNA mutations. The active drug was idebenone 900 mg/day. The primary end-point was the best recovery in visual acuity. The main secondary end-point was the change in best visual acuity. Other secondary end-points were changes in visual acuity of the best eye at baseline and changes in visual acuity for both eyes in each patient. Colour-contrast sensitivity and retinal nerve fibre layer thickness were measured in subgroups. Idebenone was safe and well tolerated. The primary end-point did not reach statistical significance in the intention to treat population. However, post hoc interaction analysis showed a different response to idebenone in patients with discordant visual acuities at baseline; in these patients, all secondary end-points were significantly different between the idebenone and placebo groups. This first randomized controlled trial in the mitochondrial disorder, Leber's hereditary optic neuropathy, provides evidence that patients with discordant visual acuities are the most likely to benefit from idebenone treatment, which is safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therapy for LHON has been restricted to supportive measures rather than cure.10”
From Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 Gene: A Secondary Analysis of a Phase 1/2 Clinical Trial (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Current treatments for LHON remain inadequate.8 Idebenone (Raxone, Santhera GmbH) was granted market authorization by the European Medicines Agency (EMA) for the treatment of LHON under exceptional circumstances, 9,10 but its benefits are limited.”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
Linear mixed models for longitudinal data
(2000) · Springer Series in Statistics · doi:10.1007/b98969 · Cited by 818
Lange, C., Feltgen, N., Junker, B., Schulze-Bonsel, K., & Bach, M. (2009) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0926-0 · Cited by 626 · cited 1×
“Patients only able to count fingers, detect hand motion or light perception were assigned logMAR values 2.0, 2.3 and 2.6, respectively (Lange et al., 2009).”
BackgroundInfluentialRiordan-Eva, P., Sanders, M. D., Govan, G. G., Sweeney, M. G., Costa, J. D., & Harding, A. E. (1995) · Brain · doi:10.1093/brain/118.2.319 · Cited by 490
The Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England
Man, P. Y. W., Griffiths, P. G., Brown, D. T., Howell, N., Turnbull, D. M., & Chinnery, P. F. (2003) · The American Journal of Human Genetics · doi:10.1086/346066 · Cited by 483 · cited 1×
“Leber’s hereditary optic neuropathy (LHON; MIM 535000) is the most common mitochondrial disorder affecting more than 1:14 000 males (Man et al., 2003).”
BackgroundSelf-citationNewman, N. J., Lott, M. T., & Wallace, D. C. (1991) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)76784-4 · Cited by 403 · cited 3×
“Most remain legally blind, are unable to drive a motor vehicle, and are unable to find employment (Newman et al., 1991; Riordan-Eva et al., 1995; Nikoskelainen et al., 1996).”
BackgroundResultInfluentialThe epidemiology of mitochondrial disorders—past, present and future
Schaefer, A. M., Taylor, R. W., Turnbull, D. M., & Chinnery, P. F. (2004) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2004.09.005 · Cited by 396 · cited 1×
“Inherited disorders of mitochondrial energy metabolism are a major cause of metabolic disease affecting more than 1/5000 of the population (Schaefer et al., 2004).”
BackgroundSelf-citationBARBONI, P., SAVINI, G., VALENTINO, M., MONTAGNA, P., CORTELLI, P., DENEGRI, A., SADUN, F., BIANCHI, S., LONGANESI, L., & ZANINI, M. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2004.06.034 · Cited by 247 · cited 14×
“Leber’s hereditary optic neuropathy (LHON; MIM 535000) is the most common mitochondrial disorder affecting more than 1:14 000 males (Man et al., 2003).”
BackgroundInfluential
Research works printed but not linked: 1
- Harding AE Sweeney MG Govan GG Riordan-Eva P Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation Am J Hum Genet 1995 57 77 86 7611298 PMC1801226
Cited by
Items 201–300 of 574
Wiggs, J. L. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147734 · Cited by 19
“Currently, there is no curative therapy; however, in some cases vision can spontaneously improve (5) and idebenone treatment can also restore vision in some patients (6).”
BackgroundYu, A. K., Datta, S., McMackin, M. Z., & Cortopassi, G. A. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx373 · Cited by 22
“which is currently supported as a drug for LHON treatment (16).”
BackgroundCyclosporine A does not prevent second-eye involvement in Leber’s hereditary optic neuropathy
Leruez, S., Verny, C., Bonneau, D., Procaccio, V., Lenaers, G., Amati‐Bonneau, P., Reynier, P., Scherer‐Gagou, C., Prundean, A., Orssaud, C., et al. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0773-y · Cited by 23
“In a randomized, placebo-controlled clinical trial, LHON patients received either 900 mg/day of idebenone or placebo [8].”
Treatment for mitochondrial diseases
Liufu, T., & Wang, Z.-X. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0034 · Cited by 21
“Klopstock et al. (2011) performed a multicenter double-blind, randomized, placebo-controlled trial of 85 patientswith LHON (57withm.11778G >Amutation, 17with m.14484T > C mutation, 11 with m.3460G > A mutation), with 900 mg/day of idebenone (300 mg three times a day during meals) or placebo for 24…”
BackgroundMethodClinical features of mtDNA-related syndromes in adulthood
Montano, V., Gruosso, F., Simoncini, C., Siciliano, G., & Mancuso, M. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108689 · Cited by 18
Karanjia, R., Yu‐Wai‐Man, P., & Newman, N. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_45 · Cited by 18
Self-citationVisual field variability after gene therapy for Leber’s hereditary optic neuropathy
Yuan, J.-J., Zhang, Y., Wang, L.-L., Cheng, M.-S., Ma, S.-Q., Gao, Q., & Li, B. (2018) · Ophthalmic Research · doi:10.1159/000487485 · Cited by 17
Chang, M. Y. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-227109 · Cited by 17
The Present and Future of Mitochondrial-Based Therapeutics for Eye Disease
Ji, M. H., Kreymerman, A., Belle, K. C., Ghiam, B. K., Muscat, S. P., Mahajan, V. B., Enns, G. M., Mercola, M. A., & Wood, E. H. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.8.4 · Cited by 20
Spiegel, S. J., & Sadun, A. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113205 · Cited by 20
“In 2011 a randomized clinical trial “Rescue of Hereditary Optic Disease Outpatient Study” (RHODOS) presented evidence that idebenone can be beneficial to preserve and/or restore vision [51].”
BackgroundRecent advances in small molecules for improving mitochondrial disorders
Meng, L., & Wu, G. (2023) · RSC Advances · doi:10.1039/d3ra03313a · Cited by 21
COQ6 mutation in patients with nephrotic syndrome, sensorineural deafness, and optic atrophy
Perrin, R. J., Rousset‐Rouvière, C., Garaix, F., Cano, A., Conrath, J., Boyer, O., & Tsimaratos, M. (2020) · JIMD Reports · doi:10.1002/jmd2.12068 · Cited by 17
Genetic and phenotypic variability of optic neuropathies
Neuhann, T., & Rautenstrauss, B. W. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.19 · Cited by 18
Leber hereditary optic neuropathy – Therapeutic challenges and early promise
Yu‐Wai‐Man, P., & Chinnery, P. F. (2011) · Taiwan Journal of Ophthalmology · doi:10.1016/j.tjo.2011.09.001 · Cited by 16
Self-citationTargeting mitochondrial function to protect against vision loss
Chhetri, J., & Gueven, N. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1134489 · Cited by 16
Neuroprotection in Optic Neuropathy
Levin, L. A. (2018) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2018299 · Cited by 18
Therapeutical Management and Drug Safety in Mitochondrial Diseases—Update 2020
Gruosso, F., Montano, V., Simoncini, C., Siciliano, G., & Mancuso, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010094 · Cited by 17
Mitochondrial dysfunction affecting visual pathways
Leruez, S., Amati‐Bonneau, P., Verny, C., Reynier, P., Procaccio, V., Bonneau, D., & Miléa, D. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.03.009 · Cited by 19
Goldschmidt, R., Arce, P. M., Khdour, O. M., Collin, V. C., Dey, S., Jaruvangsanti, J., Fash, D. M., & Hecht, S. M. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.051 · Cited by 21
Wang, R., Bao, F., Lu, M., Jia, X., Xiao, J., Wu, Y., Zhang, Q., & Liu, X. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2647-8 · Cited by 18
“MSCs have been shown to possess the ability to migrate to sites of injury or inflammation, contributing to tissue repair and regeneration (Le Blanc, 2003).”
Therapies for Mitochondrial Disease: Past, Present, and Future
Ball, M., Bergen, N. J. V., Compton, A. G., Thorburn, D. R., Rahman, S., & Christodoulou, J. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70065 · Cited by 24
“However, on subgroup analysis, it was found that idebenone may have benefit for those individuals with discordant visual acuity [90].”
Mitochondrial Diseases: Molecular Pathogenesis and Therapeutic Advances
Mei, J., Ding, P., Gao, C., Zhou, J., Li, Z., Zhang, C., & Gao, J. (2025) · MedComm · doi:10.1002/mco2.70385 · Cited by 20
“The RHODOS trial demonstrated that idebenone stabilized or improved visual acuity in over 50% of treated LHON patients versus 20% in placebo ( p = 0.005) [92].”
InfluentialYu, W., Jiang, W., Wu, W., Wang, G., Zhao, D., Yan, C., & Lin, P. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175911 · Cited by 17
The Elusive Magic Pill: Finding Effective Therapies for Mitochondrial Disorders
Goldstein, A. C., & Wolfe, L. A. (2013) · Neurotherapeutics · doi:10.1007/s13311-012-0175-0 · Cited by 17
Die randunscharfe Papille: eine diagnostische Herausforderung
Biermann, J., & Lagrèze, W. A. (2017) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-0043-108489 · Cited by 16
Mitochondrial Disorders of the Nervous System: A Review
Set, K. K., Sen, K., Huq, A. H. M. M., & Agarwal, R. L. (2019) · Clinical Pediatrics · doi:10.1177/0009922818821890 · Cited by 15
Peron, C., Maresca, A., Cavaliere, A., Iannielli, A., Broccoli, V., Carelli, V., Meo, I. D., & Tiranti, V. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.648916 · Cited by 15
Pagano, G., Pallardó, F. V., Lyakhovich, A., Tiano, L., & Trifuoggi, M. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04007-1 · Cited by 17
Borrelli, E., Berni, A., Cascavilla, M. L., Barresi, C., Battista, M., Lari, G., Reibaldi, M., Bandello, F. M., & Barboni, P. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.11.004 · Cited by 17
Leber Hereditary Optic Neuropathy: Bringing the Lab to the Clinic
Rasool, N., Lessell, S., & Cestari, D. M. (2016) · Seminars in Ophthalmology · doi:10.3109/08820538.2015.1115251 · Cited by 15
Mitra, S., Rauf, A., Sutradhar, H., Sadaf, S., Hossain, M. J., Soma, M. A., Emran, T. B., Ahmad, B., Aljohani, A. S. M., Abdulmonem, W. A., et al. (2022) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2022.109509 · Cited by 15
Therapeutic strategies for Leber’s hereditary optic neuropathy: A current update
Gueven (2013) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2013.v2.4.130 · Cited by 14
Keep the fire burning: Current avenues in the quest of treating mitochondrial disorders
Tischner, C., & Wenz, T. (2015) · Mitochondrion · doi:10.1016/j.mito.2015.06.002 · Cited by 17
Tonagel, F., Wilhelm, H. M., Richter, P., & Kelbsch, C. (2020) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-05045-4 · Cited by 18
Neuron-Specific Enolase Is Elevated in Asymptomatic Carriers of Leber's Hereditary Optic Neuropathy
Yee, K. M. P., Ross‐Cisneros, F. N., Lee, J. G., da Rosa, A. B., Salomão, S. R., Berezovsky, A., Belfort, R., Chicani, F., Moraes-Filho, M. N., Sebag, J., et al. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9677 · Cited by 14
Secondary coenzyme Q deficiency in neurological disorders
Guéguen, N., Baris, O. R., Lenaers, G., Reynier, P., & Spinazzi, M. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.01.017 · Cited by 14
Metabolic, Hereditary, Traumatic, and Neoplastic Optic Neuropathies
Stavern, G. P. V. (2014) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000453313.37143.9b · Cited by 14
Leber Hereditary Optic Neuropathy: A Mitochondrial Disease Unique in Many Ways
Bi, R., Logan, I., & Yao, Y. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_1 · Cited by 16
“In recent years, more evidence has shown that LHON patients might benefit from idebenone treatment (Carelli et al. 2011; Klopstock et al. 2011, 2013), suggesting that agents active against complex I dysfunction and oxidative stress may be an efficient treatment for LHON in the future (Fig.”
BackgroundLeber hereditary optic neuropathy: new and emerging therapies
Davila-Siliezar, P. A., Carter, M. W., Miléa, D., & Lee, A. G. (2022) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000891 · Cited by 13
Mitochondrial aberrations and ophthalmic diseases
Abu‐Amero, K. K., Kondkar, A. A., & Chalam, K. V. (2016) · Journal of Translational Science · doi:10.15761/jts.1000167 · Cited by 13
“Initial studies have suggested that oral administration of Idebenone (trade name, Raxone®) could benefit early-stage LHON patients at high risk for further visual loss [23-25].”
BackgroundRadelfahr, F., & Klopstock, T. (2019) · Der Nervenarzt · doi:10.1007/s00115-018-0666-2 · Cited by 16
Self-citationLeberʼsche hereditäre Optikusneuropathie
Priglinger, C., Klopstock, T., Rudolph, G., & Priglinger, S. G. (2019) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-0972-1552 · Cited by 19
Self-citationKurimoto, T., Ueda, K., Mori, S., Kamada, S., Sakamoto, M., Yamada‐Nakanishi, Y., Matsumiya, W., & Nakamura, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051359 · Cited by 13
“Previously, several clinical trials have attempted to improve vision by using idebenone, coenzyme Q10 derivatives [4], EPI-473 [5], and gene therapy via an adeno-associated virus serotype 2 (AAV2) vector [6].”
BackgroundMethodOptic Neurodegeneration: Time to Act
Gueven, N. (2014) · Biology and Medicine · doi:10.4172/0974-8369.s1-001 · Cited by 13
“In this trial, idebenone improved visual acuity particularly in LHON patients with recent disease onset but not in patients of the placebo group [52,53].”
BackgroundResultTargeting adaptive cellular responses to mitochondrial bioenergetic deficiencies in human disease
Bennett, C. F., Ronayne, C. T., & Puigserver, P. (2021) · FEBS Journal · doi:10.1111/febs.16195 · Cited by 13
“201 Szeto HH (2017) Pharmacologic Approaches to Improve Mitochondrial Function in AKI and CKD.”
BackgroundLayrolle, P., Orssaud, C., Leleu, M., Payoux, P., & Chavanas, S. (2024) · Biomedicines · doi:10.3390/biomedicines12030584 · Cited by 15
“…LHON patient after IDB treatment as early as 1992 [99] and after other case reports, a prospective, placebo-controlled study with 85 LHON patients [100] and two retrospective analyses of cohorts of 103 or 111 LHON patients [8,101] convergently showed that IDB stabilized or improved visual…”
ResultCurrent progress in the therapeutic options for mitochondrial disorders.
Koňaříková, E., Markovic, A., Korandová, Z., Houštěk, J., & Mráček, T. (2020) · Physiological Research · doi:10.33549/physiolres.934529 · Cited by 16
Erythropoietin and Friedreich Ataxia: Time for a Reappraisal?
Boesch, S., & Indelicato, E. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00386 · Cited by 12
“FRDA has been the testing field for compounds which were further developed for the treatment of other disorders (Klopstock et al., 2011; Reata Pharmaceuticals, Inc., 2017) as well as the first neurodegenerative disease in which Erythropoietin (EPO) advanced to clinical trials (Boesch et al.”
BackgroundGrochowski, C., Symms, M. R., Jonak, K., Krukow, P., Wood, T., Ljungberg, E., Enseñat, J., Nowomiejska, K., Ręjdak, R., Maciejewski, R., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041112 · Cited by 12
Late‐onset L eber hereditary optic neuropathy
Pfeiffer, M. L., Hashemi, N., Foroozan, R., & Lee, A. G. (2013) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12091 · Cited by 12
From Bench to Bedside—Delivering Gene Therapy for Leber Hereditary Optic Neuropathy
Chen, B. S., & Yu‐Wai‐Man, P. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041282 · Cited by 14
Self-citationClinical trials in Leber hereditary optic neuropathy: outcomes and opportunities
Chen, B. S., & Newman, N. J. (2024) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001343 · Cited by 12
Ganesh, J., & Scaglia, F. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817344-2.00018-6 · Cited by 11
Vitamin B12 in Leber hereditary optic neuropathy mutation carriers: a prospective cohort study
Zibold, J., von Livonius, B., Kolářová, H., Rudolph, G., Priglinger, C., Klopstock, T., & Catarino, C. B. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02453-z · Cited by 11
Self-citationBorrelli, E., Berni, A., Mastropasqua, L., Querques, G., Sadda, S. R., Sarraf, D., & Bandello, F. M. (2023) · Ophthalmologica · doi:10.1159/000533910 · Cited by 11
Stephenson, K. A. J., McAndrew, J., Kenna, P. F., & Cassidy, L. (2022) · Neuro-Ophthalmology · doi:10.1080/01658107.2022.2032761 · Cited by 11
“The RHODOS trials showed idebenone (900 mg/day) gave benefit for genetically confirmed LHON for up to 30 months in patients < 5 years from onset (particularly with the 11778 or 3460 mutations), thus early genetic confirmation is essential to access this treatment.(29,48,52,53) Half of our cohort were prescribed ideben…”
BackgroundSubramaniam, M. D., Chirayath, R. B., Iyer, M., Nair, A. P., & Vellingiri, B. (2022) · International Ophthalmology · doi:10.1007/s10792-022-02267-9 · Cited by 11
Neurologic Disorders Due to Mitochondrial DNA Mutations
DeBrosse, S. D., & Parikh, S. (2012) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2012.09.006 · Cited by 11
Yuan, J., Zhao, J., Ye, C., Pang, L., Zhang, X., Luk, A. Y., Du, Y., Fan, K. Y., Zhang, X., Li, B., et al. (2023) · BioMed Research International · doi:10.1155/2023/1107866 · Cited by 10
“In a phase II multicentre, double-blind, randomized, placebo-controlled trial of idebenone conducted among 85 LHON patients [76], the di ff erence between the treatment and placebo group in the best recovery of VA between baseline and week 24 did not meet statistical signi fi cance, while signi fi…”
Gene therapy for Leber hereditary optic neuropathy
Battista, M., Carelli, V., Bottazzi, L., Bandello, F. M., Cascavilla, M. L., & Barboni, P. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2359015 · Cited by 10
“In the pivotal (RHODOS trial) and real-world studies, however, the efficacy of idebenone varies greatly depending on the LHON mutation considered, with a significant clinical recovery from 39% in ND4 patients to 76% in ND6 patients [64,65].”
BackgroundVision improvement in a Taiwanese (Han Chinese) family with Leber's hereditary optic neuropathy
Lin, H.-Z., Pang, C., Chen, S., & Tsai, R. (2012) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2012.04.038 · Cited by 9
“Recently, one randomized controlled trial found that treatment with high-dose idebenone (900 mg/day) for 24 weeks had therapeutic effects in LHON patients with discordant baseline visual acuities [22].”
BackgroundDrug Development for Rare Mitochondrial Disorders
Hurko, O. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0179-4 · Cited by 12
Mitochondrial DNA mutation 14487T>C manifesting as Leber’s hereditary optic neuropathy
Eckenweiler, M., Catarino, C. B., Gallenmüller, C., Klopstock, T., Lagrèze, W. A., Korinthenberg, R., & Kirschner, J. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7955-5 · Cited by 10
Self-citationTreatment and Management of Hereditary Metabolic Myopathies
Vorgerd, M., & Deschauer, M. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0372-6.00022-0 · Cited by 10
Chadderton, N., Palfi, A., Maloney, D. M., Carrigan, M., Finnegan, L. K., Hanlon, K. S., Shortall, C., O’Reilly, M., Humphries, P., Cassidy, L., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020322 · Cited by 9
“Notably, Raxone®, a synthetic CoQ10 analogue was approved by the European Medicines Agency (EMA) to treat LHON in 2015 [99,100], and LUMEVOQ®, an allotopic ND4 gene replacement therapy for the most common LHON mtDNA mutation (m.”
BackgroundLeber Hereditary Optic Neuropathy
Yu‐Wai‐Man, P., & Chinnery, P. F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800877-5.00007-3 · Cited by 9
Self-citationIdebenone Treatment in Patients with OPA1-Dominant Optic Atrophy: A Prospective Phase 2 Trial
Valentin, K., Georgi, T., Riedl, R., Aminfar, H., Singer, C., Klopstock, T., Wedrich, A., & Schneider, M. R. (2023) · Neuro-Ophthalmology · doi:10.1080/01658107.2023.2251575 · Cited by 10
“Colour vision was tested with the Ishihara plates at a distance of 75 cm with 38 plates presented in a well-illuminated location; 21 of them counted for the test, and the remaining 17 were placebo plates.”
MethodSelf-citationOptions for Topical Treatment of Oxidative Eye Diseases with a Special Focus on Retinopathies
Russo, C., Rusciano, D., Santangelo, R., & Malaguarnera, L. (2024) · Medicina · doi:10.3390/medicina60030354 · Cited by 10
“LHON is a genetic disorder affecting the optic nerve, and idebenone’s ability to mitigate the effects of mitochondrial dysfunction in this context has significant implications for the treatment of this condition [95].”
BackgroundUncommon Leber “Plus” Disease Associated With Mitochondrial Mutation m.11778G>A in a Premature Child
Paquay, S., Benoît, V., Wetzburger, C., Cordonnier, M., Meire, F. M., Charon, A., Roland, D., Coster, R. V., Nassogne, M., & Maystadt, I. (2013) · Journal of Child Neurology · doi:10.1177/0883073813492895 · Cited by 9
“Treatment with biperiden was initiated, and based on recent studies supporting idebenone’s beneficial effect on Leber optic neuropathy, this latter medication replaced ubiquinone.(20-22)”
MethodOverview of Approaches to Mitochondrial Disease Therapy
Lehmann, D., & McFarland, R. (2018) · Journal of Inborn Errors of Metabolism and Screening · doi:10.1177/2326409817752960 · Cited by 10
“The marked decrease in visual acuity experienced during the acute phase of LHON is thought to be a consequence of respiratory chain dysfunction in viable, but inactive, retinal ganglion cells.19 Idebenone is known to preserve or reestablish retinal ganglion cell function during the acute phase and thus protects from i…”
BackgroundOxford Handbook of Clinical Specialties
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · doi:10.1093/med/9780198719021.001.0001 · Cited by 9
Neuropathies optiques héréditaires
Miléa, D., & Verny, C. (2012) · Revue Neurologique · doi:10.1016/j.neurol.2012.08.005 · Cited by 10
Leber’s hereditary optic neuropathy - Case report
Iorga, R. E., Mihailovici, R., Ozturk, M. R., & Costin, D. (2018) · Romanian Journal of Ophthalmology · doi:10.22336/rjo.2018.9 · Cited by 9
Clinical Therapeutic Management of Human Mitochondrial Disorders
Finsterer, J. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2020.07.004 · Cited by 11
Lott, L. B. D. (2025) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/cont.0000000000001545 · Cited by 8
The current landscape for the treatment of mitochondrial disorders
Slone, J. D., Gui, B., & Huang, T. (2018) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2017.11.008 · Cited by 9
Analysis of Inherited Optic Neuropathies
Lazdinyte, S., Schorderet, D. F., Schaller, A., Valmaggia, C., & Todorova, M. G. (2019) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-0829-6828 · Cited by 7
New avenues for therapy in mitochondrial optic neuropathies
Ng, V., Trigano, M., Freeman, T. J., Varricchio, C., Kandaswamy, S., Newland, B., Brancale, A., Rôżanowska, M., & Votruba, M. (2021) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040211029037 · Cited by 12
Brodsky, M. C. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3384-6_4 · Cited by 8
Baltă, G., Cristache, G., Barac, A. D., Anton, N., & Barac, I. R. (2023) · Life · doi:10.3390/life13102000 · Cited by 10
“However, if the patient shows no improvement, the treatment should be ceased after 24 months.”
BackgroundMitochondrial Genetics and Optic Neuropathy
Wiggs, J. L. (2015) · Annual Review of Vision Science · doi:10.1146/annurev-vision-082114-035651 · Cited by 8
Novel use of idebenone in Leber’s hereditary optic neuropathy in Hong Kong
Cheng, S., Ko, C., Yau, S., Mak, C. M., Yuen, Y., & Lee, C. (2014) · Hong Kong Medical Journal · doi:10.12809/hkmj134085 · Cited by 8
Use of Idebenone for the Treatment of Leber’s Hereditary Optic Neuropathy: Review of the Evidence
Catarino, C. B., & Klopstock, T. (2017) · Journal of Inborn Errors of Metabolism and Screening · doi:10.1177/2326409817731112 · Cited by 9
“The results of this multicenter RCT to assess efficacy, safety, and tolerability of the treatment with idebenone in LHON were published in 2011.(11) In this phase III RCT, called “Rescue of Hereditary Optic Disease Outpatient Study” (RHODOS; NCT00747487), 85 patients were enrolled with LHON caused by one of the three…”
BackgroundMethodInfluentialSelf-citationPineles, S. L., & Balcer, L. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-34044-1.00005-5 · Cited by 8
Ocular Manifestations in Patients with Sensorineural Hearing Loss
Zaheer, H. A., Parameswarappa, D. C., Zaheer, M. A., Chhablani, J. K., & Chhablani, P. P. (2022) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v17i4.12321 · Cited by 10
Ganglion Cell Complex Thickness and Visual Function in Chronic Leber Hereditary Optic Neuropathy
Hedström, J., Nilsson, M., Engvall, M., Williams, P. A., & Venkataraman, A. P. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.12.4 · Cited by 7
“In previous studies examining the effect of idebenone, 39,40 the largest treatment effect was seen among patients with the 11778G > A ( MT-ND4 ) and 3460G > A ( MT-ND6 ) mutations.”
BackgroundMitochondrial disease and epilepsy in children
Zhang, X., Zhang, B., Tao, Z., & Liang, J. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2024.1499876 · Cited by 13
Leber’s hereditary optic neuropathy – current status of idebenone and gene replacement therapies
Klopstock, T., Zeng, L. H., & Priglinger, C. (2025) · Medizinische Genetik · doi:10.1515/medgen-2024-2066 · Cited by 10
Self-citationAntioxidant therapy in inborn metabolic diseases
Heimes, F., Berendes, L.-S., Hannibal, L., & Park, J. H. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109176 · Cited by 8
Mitochondrial encephalomyopathy
Ng, Y. S., & McFarland, R. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-98818-6.00025-x · Cited by 10
Reinert, M., Pacheu‐Grau, D., Catarino, C. B., Klopstock, T., Ohlenbusch, A., Schittkowski, M., Wilichowski, E., Rehling, P., & Brockmann, K. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01690-y · Cited by 7
Self-citationMitochondrial function and epigenetic outlook in Leber's Hereditary Optic Neuropathy (LHON)
Devi, S. M., Nair, A. P., Mahalaxmi, I., & Vellingiri, B. (2021) · Neurology Perspectives · doi:10.1016/j.neurop.2021.07.003 · Cited by 10
Siedlecki, J., Koenig, S. F., Catarino, C. B., Schaumberger, M. M., Schworm, B., Priglinger, S. G., Rudolph, G., von Livonius, B., Klopstock, T., & Priglinger, C. (2022) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-320580 · Cited by 8
Self-citationLeber Hereditary Optic Neuropathy: Molecular Pathophysiology and Updates on Gene Therapy
Chi, S.-C., Cheng, H., & Wang, A.-G. (2022) · Biomedicines · doi:10.3390/biomedicines10081930 · Cited by 8
“A clinical trial of idebenone showed that the secondary endpoint of change in best-corrected visual acuity was significantly better with Raxone use, while the primary endpoint of best recovery in visual cuity did not reach statistical significance [28].”
BackgroundBaglivo, M., Nasca, A., Lamantea, E., Vinci, S., Spagnolo, M., Marchet, S., Prokisch, H., Catania, A., Lamperti, C., & Ghezzi, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612580 · Cited by 8
“However, some other studies question the clinical effect of idebenone treatment, struggling to distinguish a placebo from idebenone’s effects [13].”
Maculopapillary Bundle Degeneration in Optic Neuropathies
Lambiri, D. W., & Levin, L. A. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01343-0 · Cited by 7
“Idebenone, a synthetic coenzyme Q that passes the blood–brain barrier, was initially formulated to address complex I deficiencies in LHON [79, 80].”
Mitochondrial Biology and Medicine
Wallace, D. C., Lott, M. T., & Procaccio, V. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812537-3.00010-x · Cited by 8
A case of reversible toxic optic neuropathy from tacrolimus (FK506)
Gokoffski, K. K., & Patel, V. R. (2020) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2020.100932 · Cited by 7
Wallace, D. C., Lott, M. T., & Procaccio, V. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00013-6 · Cited by 10
Wolfram Syndrome: A case report of two sisters Wolfram Syndrome: Case report of two sisters
Rotsos, T., Papakonstantinou, E., Symeonidis, C., Krassas, A., & Kamakari, S. (2022) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2022.101452 · Cited by 7
Metadata
- Authors
- Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., Kernt, M., Petraki, D., Rummey, C., Leinonen, M., Metz, G., Griffiths, P. G., Meier, T., & Chinnery, P. F.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- 2 Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne Foundation Hospital, NE1 4LP, NHS Trust, UK
- Centre Hospitalier de l’Université de Montréal (CA)
- Royal Victoria Infirmary (GB)
- Santhera Pharmaceuticals (Switzerland) (CH)
- 8 4Pharma, Stockholm, 16440 Kista, Sweden
- Corresponding author
- Chinnery, Patrick F.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07-23
- Volume
- 134
- Issue
- 9
- Pages
- 2677-2686
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3170530
- OpenAlex
- W2124154990
- Cited by
- 578
- References
- 32
- Citations by year
- 2026: 25 · 2025: 35 · 2024: 41 · 2023: 36 · 2022: 44 · 2021: 42 · 2020: 69 · 2019: 39 · 2018: 31 · 2017: 28 · 2016: 61 · 2015: 28 · 2014: 28 · 2013: 29 · 2012: 29
- FWCI
- 16.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Wellcome Trust (01GM0862)
- National Institute for Health and Care Research (NF-SI-0509-10011)
- Parkinson's UK
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung (01GM0862)
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- idebenone, Leber's hereditary optic neuropathy, mitochondrial DNA mutations, mitochondrial disease, visual acuity, retinal nerve fiber layer thickness, treatment response heterogeneity, drug safety and tolerability
- MeSH terms
- Adolescent, Adult, Aged, Antioxidants, DNA, Mitochondrial, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Placebos, Prospective Studies, Retina, Ubiquinone, Visual Acuity, Contrast Sensitivity, Optic Atrophy, Hereditary, Leber, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.